ARTICLE | Company News
FDA panel votes for additional Certican data
November 18, 2005 3:25 AM UTC
FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-6 recommending submission of additional data for Certican everolimus from Novartis (NVS; SWX:NOVN) to prevent rejection in heart transpl...